Search Result

Results for "

RIPK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	RIP kinase (136) 11β-HSD (2) AAK1 (1) Akt (2) AMPK (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (16) Aurora Kinase (1) Autophagy (5) Bcr-Abl (1) Beclin1 (1) CaMK (2) Caspase (5) CaSR (2) CDK (7) Cyclin G-associated Kinase (GAK) (3) DYRK (2) EGFR (1) Epigenetic Reader Domain (1) ERK (3) Ferroptosis (6) GSK-3 (2) HIV (1) HSP (1) IAP (2) Influenza Virus (1) Integrin (1) Interleukin Related (6) Keap1-Nrf2 (3) Lactate Dehydrogenase (1) Ligands for Target Protein for PROTAC (2) LIM Kinase (LIMK) (2) MAP4K (1) MAPKAPK2 (MK2) (1) MEK (1) MELK (2) Mixed Lineage Kinase (17) mTOR (2) Necroptosis (27) NF-κB (5) NOD-like Receptor (NLR) (5) p38 MAPK (6) PARP (4) PI3K (2) Pim (2) PROTAC Linkers (2) PROTACs (11) Raf (1) Reactive Oxygen Species (ROS) (2) Reference Standards (8) Salt-inducible Kinase (SIK) (2) SARS-CoV (1) Ser/Thr Kinase (1) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (12) Sodium Channel (1) STAT (1) STING (2) Target Protein Ligand-Linker Conjugates (2) Tau Protein (1) TGF-beta/Smad (2) TGF-β Receptor (3) TNF Receptor (4) Toll-like Receptor (TLR) (1) Topoisomerase (1) ULK (3) VEGFR (2) Virus Protease (1)
By Research Areas:	Cancer (52) Cardiovascular Disease (7) Endocrinology (2) Infection (9) Inflammation/Immunology (90) Metabolic Disease (7) Neurological Disease (24)
Oligonucleotides:	Rat Pre-designed siRNA Sets (4) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (4) siRNAs (12)

157

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: RIP kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101872

GSK-872 Maximum Cited Publications 100 Publications Verification	RIP kinase	Inflammation/Immunology
GSK-872 is a *RIPK3* inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 1.8 nM, and inhibits kinase activity with an IC₅₀ of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .

HY-101872A

GSK-872 hydrochloride Maximum Cited Publications 100 Publications Verification	RIP kinase	Inflammation/Immunology
GSK-872 hydrochloride is a *RIPK3* inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 1.8 nM, and inhibits kinase activity with an IC₅₀ of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .

HY-111866

*PROTAC RIPK* degrader-2** 1 Publications Verification	PROTACs RIP kinase	Metabolic Disease Cancer
PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase *RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK* degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the *RIPK1/RIPK3/MLKL* pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-18937

WEHI-345 3 Publications Verification	RIP kinase	Cancer
WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC₅₀ of 0.13 μM, which delays *RIPK2* ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .

HY-171658

R1-ICR-5	PROTACs Ser/Thr Kinase TNF Receptor Toll-like Receptor (TLR) NF-κB p38 MAPK	Inflammation/Immunology Cancer
R1-ICR-5 is a highly selective *RIPK1* PROTAC degrader. Mediated by VHL, R1-ICR-5 induces the degradation of RIPK1, which in turn dysregulates the TNFR1 and TLR3/4 signaling hubs, enhances the signaling outputs of NF-κB, MAPK and IFN, and simultaneously promotes *RIPK3* activation and necroptosis (necroptosis). R1-ICR-5 can be used in the research of triple-negative breast cancer and skin inflammation .

HY-131064

RIPK3-IN-1 1 Publications Verification	RIP kinase	Inflammation/Immunology
RIPK3-IN-1 is a *RIPK3* type II DFG-out inhibitor with an IC₅₀ of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC₅₀s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC₅₀ of 1.1 μM .

HY-115630

cRIPGBM chloride	RIP kinase Caspase Apoptosis	Cancer
cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of *RIPK2/TAK1* (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models .

HY-128348

PK68	RIP kinase	Inflammation/Immunology Cancer
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC₅₀ of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .

HY-119933

RIPK1-IN-7	RIP kinase	Cancer
RIPK1-IN-7 is a potent and selective *RIPK1* inhibitor with a K_d of 4 nM and an enzymatic IC₅₀ of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model .

HY-107978

RIPK-IN-4 2 Publications Verification	RIP kinase	Inflammation/Immunology
RIPK-IN-4 is a selective *RIPK2* inhibitor with an IC₅₀ value of 3 nM. RIPK-IN-4 can be used for the research of inflammatory diseases .

HY-132203

Necrostatin-34	RIP kinase	Inflammation/Immunology Cancer
Necrostatin-34 (Nec-34), a *RIPK1* kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain .

HY-175370

*PROTAC RIPK1 Degrader-1*	PROTACs RIP kinase	Cancer
PROTAC RIPK1 Degrader-1 is a selective *RIPK1* PROTAC degrader. PROTAC RIPK1 Degrader-1 degrades *RIPK1* in multiple cancer cell lines (e.g., A375, B16F10 cells). PROTAC RIPK1 Degrader-1 enhances the anti-cancer effect of radiotherapy in syngeneic and humanized mouse models. PROTAC RIPK1 Degrader-1 can be used to study cancers such as melanoma. (Pink: RIPK1-ligand-2: HY-175371, Blue: (S,R,S)-AHPC-Me: HY-112078, Pink + Black: RIPK1 ligand-Linker Conjugate-1: HY-175374, Black: Bispiperidin-piperazin-acetater: HY-175373) .

HY-18901

RIPK1-IN-4	RIP kinase	Inflammation/Immunology
RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC₅₀s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase .

HY-111870

*PROTAC RIPK* degrader-6**	PROTACs RIP kinase	Cancer
PROTAC RIPK degrader-6 (example 1) is a Cereblon-based PROTAC targeting RIP Kinase degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder .

HY-157456

RIPK1-IN-19	RIP kinase	Inflammation/Immunology
RIPK1-IN-19 is a selective *RIPK1* inhibitor (IC₅₀=15 nM). RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases .

HY-157325

RIPK2-IN-5	RIP kinase	Inflammation/Immunology
RIPK2-IN-5 (compound 14) is a high affinity and excellent selectivity RIPK2 inhibitor with an IC₅₀ value of 5.1nM. RIPK2-IN-5 has cellular anti-inflammatory effect and can reduce the secretion of MDP-induced TNF-α with a dose-dependent manner. RIPK2-IN-5 shows moderate stability in human liver microsome. RIPK2-IN-5 can be used for the research of immune diseases .

HY-151873

SZM679	RIP kinase	Inflammation/Immunology Cancer
SZM679 is a potent, orally active and selective *RIPK1* inhibitor with K_d values of 8.6 nM and >5000 nM for RIPK1 and RIPK3, respectively. SZM679 reverses the tumor necrosis factor-induced systemic inflammatory response. SZM679 decreases the Tau hyperphosphorylation, neuroinflammation, and the RIPK1 phosphorylation level in the hippocampus and cortex. SZM679 can be used in research of Alzheimer's disease (AD) .

HY-148382

RI-962	RIP kinase Necroptosis	Neurological Disease Inflammation/Immunology
RI-962 is a potent and selective receptor-interacting protein kinase 1 (RIPK1) inhibitor. RI-962 inhibits RIPK1 with an IC₅₀ value of 35.0 nM. RI-962 can be used for the research of nervous system diseases and inflammatory diseases .

HY-149393

RIPK3-IN-3	Mixed Lineage Kinase RIP kinase	Cancer
RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC₅₀=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion .

HY-RS11993

Ripk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) RIP kinase	Others
Ripk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ripk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ripk1 Mouse Pre-designed siRNA Set A Ripk1 Mouse Pre-designed siRNA Set A

HY-RS11992

RIPK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) RIP kinase	Others
RIPK1 Human Pre-designed siRNA Set A contains three designed siRNAs for RIPK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RIPK1 Human Pre-designed siRNA Set A RIPK1 Human Pre-designed siRNA Set A

HY-146694

RIPK2-IN-1	RIP kinase Anaplastic lymphoma kinase (ALK)	Inflammation/Immunology
RIPK2-IN-1 (compound 18f) is a potent *RIPK2* inhibitor with an IC₅₀ of 51 nM. RIPK2-IN-1 inhibits ALK2 with an IC₅₀ of 5 nM. RIPK2-IN-1 has an IC₅₀ of 390 nM on RIPK2/NOD2 in cell assay .

HY-RS11998

RIPK3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) RIP kinase	Others
RIPK3 Human Pre-designed siRNA Set A contains three designed siRNAs for RIPK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RIPK3 Human Pre-designed siRNA Set A RIPK3 Human Pre-designed siRNA Set A

HY-136010

RIP2 Kinase Inhibitor 4	RIP kinase PROTACs	Inflammation/Immunology
RIP2 Kinase Inhibitor 4 is a potent and selective RIPK2 PROTAC. RIP2 Kinase Inhibitor 4 effectively degrades RIPK2 (pIC₅₀ of 8) and inhibits the release of related TNF-α .

HY-100112

WEHI-345 analog	RIP kinase	Others
WEHI-345 analog is the analog of WEHI-345. WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC₅₀ of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .

HY-157039

RIPK1-IN-17	RIP kinase Necroptosis Mixed Lineage Kinase	Inflammation/Immunology
RIPK1-IN-17 is an orally active, selective *RIPK1* inhibitor (K_d = 17 nM) and shows no significant inhibition to RIPK3. RIPK1-IN-17 specifically inhibits necroptosis rather than apoptosis by inhibiting *RIPK1, RIPK3, and MLKL* phosphorylation. RIPK1-IN-17 protects mice from hypothermia and death. RIPK1-IN-17 can be used for the study of necroptosis-related diseases such as inflammatory response syndrome (SIRS) .

HY-175026

RIPK2-IN-8	RIP kinase NF-κB p38 MAPK Interleukin Related	Inflammation/Immunology
RIPK2-IN-8 is an orally active and highly selective *RIPK2* inhibitor (IC₅₀ = 11 nM). RIPK2-IN-8 is highly selective for *RIPK2* over *RIPK1* (IC₅₀ > 30,000 nM) and has a moderate inhibitory effect on *RIPK3* (IC₅₀ = 44.61 nM). RIPK2-IN-8 inhibits the NOD2-RIPK2 signaling pathway and the expression of the inflammatory cytokines IL-6 and TNFα, thereby exerting anti-inflammatory effects. RIPK2-IN-8 has demonstrated anti-inflammatory and hepatoprotective effects in an acute liver injury (ALI) model and can be used in ALI research .

HY-171986

RIPK3-IN-6	RIP kinase	Cancer
RIPK3-IN-6 (compound 1) is a type I *RIPK3* inhibitor with poor selectivity for the RIPK family, especially for RIPK2 activity .

HY-178464

RIPK1-IN-34	RIP kinase Mixed Lineage Kinase Necroptosis	Neurological Disease Inflammation/Immunology
RIPK1-IN-34 is a selective, brain-penetrant RIPK1 inhibitor (IC₅₀ = 126.70 nM) with almost no inhibitory effect on RIPK3 (IC₅₀ ＞ 10, 000 nM). RIPK1-IN-34 offers substantial neuroprotection by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) within the necroptosis pathway. RIPK1-IN-34 shows the neuroprotective effect in a rat middle cerebral artery occlusion (MCAO) model. RIPK1-IN-34 can be used for the study of anti-acute ischemic stroke (AIS) .

HY-175371

RIPK1-ligand-2	RIP kinase Ligands for Target Protein for PROTAC	Cancer
RIPK1-ligand-2 is a *RIPK1* inhibitor. RIPK1-ligand-2 can be used for synthesis of PROTAC RIPK1 Degrader-1 (HY-175370) .

HY-143726

RIPK1-IN-8	RIP kinase	Inflammation/Immunology
RIPK1-IN-8 (example 16), an aminoimidazopyridine, is a potent and selective *RIPK1* inhibitor with an IC₅₀ of 4 nM. RIPK1-IN-8 has the potential for inflammatory diseases research .

HY-179235

RIPK1-IN-37	Ligands for Target Protein for PROTAC RIP kinase	Cancer
RIPK1-IN-37 is an *RIPK1* inhibitor and a ligand for the target protein for PROTAC LD5097 (HY-179234). RIPK1-IN-37 can be used to synthesize PROTAC .

HY-171592

RIPK2-IN-7	RIP kinase NOD-like Receptor (NLR) TNF Receptor	Inflammation/Immunology
RIPK2-IN-7 (Compound 10w) is an orally active, selective *RIPK2* inhibitor (IC₅₀: 0.6 nM). RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα). RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD) .

HY-146758

RIPK1-IN-14	RIP kinase	Neurological Disease Inflammation/Immunology
RIPK1-IN-14 (Compound 41) is a potent inhibitor of *RIPK1* with an IC₅₀ value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells .

HY-178762S

RIPK1-IN-35	RIP kinase Necroptosis	Inflammation/Immunology
RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC₅₀ of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis .

HY-157309

RIPK2-IN-4	RIP kinase	Cancer
RIPK2-IN-4 is a potent and specific *RIPK2* inhibitor with an IC₅₀ value of 5 nM .

HY-147235

RIPK2-IN-2	RIP kinase PROTACs	Infection
RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor. RIPK2-IN-2 can block RIP2-dependent proinflammatory signaling, regulated RIP2 kinase activity in auto inflammatory diseases .

HY-175374

RIPK1 ligand-Linker Conjugate-1	Target Protein Ligand-Linker Conjugates RIP kinase	Cancer
RIPK1 ligand-Linker Conjugate-1 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for *RIPK1* (HY-175371) and a PROTAC linker (HY-175373), which recruits E3 ligases. RIPK1 ligand-Linker Conjugate-1 can be used for synthesis of PROTAC RIPK1 Degrader-1 (HY-175370) .

HY-120600

Sibiriline	Necroptosis Apoptosis RIP kinase	Inflammation/Immunology
Sibiriline is a specific competitive inhibitor of *RIPK1* that targets the *RIPK1* ATP-binding site and locks it in an inactive conformation. Sibiriline inhibits TNF-induced *RIPK1*-dependent necroptosis and *RIPK1*-dependent apoptosis, but does not protect cells from caspase-dependent apoptosis. Sibiriline protects mice from concanavalin A-induced hepatitis and has the potential to inhibit immune-dependent hepatitis. .

HY-123924

CSLP37	RIP kinase	Inflammation/Immunology
CSLP37 is a selective *RIPK2* inhibitor with an IC₅₀ of 16.3 nM. CSLP37 shows no inhibitory activity against RIPK1 and RIPK3. CSLP37 displays potent suppression of cellular NOD1 and NOD2 responses .

HY-N0546R

Ligustroflavone (Standard) Nuezhenoside (Standard)	Reference Standards CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the *RIPK1/RIPK3/MLKL* pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-124643

RIPK2-IN-3	RIP kinase	Cancer
RIPK2-IN-3 (FCG806791773) is a *RIPK2* inhibitor. RIPK2-IN-3 inhibits recombinant truncated RIPK2 with an IC₅₀ of 6.39 μM. RIPK2-IN-3 can be used for research of inflammation and cancer .

HY-156367

RIPK1-IN-16	RIP kinase	Inflammation/Immunology
RIPK1-IN-16 is an orally active and potent inhibitor of *RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK*1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis .

HY-146757

RIPK1-IN-13	RIP kinase	Inflammation/Immunology
RIPK1-IN-13 (Compound 8) is a potent inhibitor of *RIPK1* with an IC₅₀ value of 1139 nM. RIPK1-IN-13 blocks the activation of the necroptosis pathway via the inhibition of RIPK1. RIPK1-IN-13 has the potential for the research of inflammation diseases .

HY-170232

RIPK1-IN-29	RIP kinase	Inflammation/Immunology
RIPK1-IN-29 (Compound 22) is a *RIPK1* inhibitor, with an IC₅₀ of 6.9 nM. RIPK1-IN-29 exerts anti-necroptotic (Apoptosis) activity by inhibiting *RIPK1. In a TNF-α-induced in vivo inflammation model, at a dose of 10 mg/kg, RIPK1-IN-29 can protect mice from hypothermia and death. RIPK*1-IN-29 can be applied to the research field of inflammatory diseases .

HY-160216

RIPK1-IN-18	RIP kinase	Inflammation/Immunology
RIPK1-IN-18 (compound i) is a potent inhibitor of *RIPK1. RIPK*1-IN-18 can be used in autoimmune diseases research .

HY-175007

RIPK1-IN-32	RIP kinase NF-κB p38 MAPK TNF Receptor Interleukin Related	Infection Inflammation/Immunology
RIPK1-IN-32 is a *RIPK* inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC₅₀ of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the *RIPK1/NF-κB/MAPK* pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis .

HY-143480

RIPK1-IN-15	RIP kinase	Neurological Disease Inflammation/Immunology
RIPK1-IN-15 (Compound 2.5) is a potent inhibitor of *RIPK1. RIPK*1-IN-15 has the potential for the research neurodegenerative, autoimmune, and inflammatory diseases .

HY-172909

RIPK3-IN-5	RIP kinase Necroptosis	Inflammation/Immunology
RIPK3-IN-5 (compound 32) is a potent *RIPK3* inhibitor with an IC₅₀ of 27 nM. RIPK3-IN-5 also inhibits necroptosis with an EC₅₀ of 0.45 μM .

Cat. No.	Product Name	Target	Research Area

HY-144277

RIPK1-IN-12	RIP kinase Necroptosis	Inflammation/Immunology
RIPK1-IN-12 is a potent *RIPK1* inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC₅₀ values of 1.6 and 2.9 nM, respectively .

HY-P10977

Tat-ASIC1a (1-20) (mouse, rat)	Sodium Channel RIP kinase	Neurological Disease
Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the *ASIC1a-RIPK1* pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2909

Aurantiamide	Alkaloids Classification of Application Fields Other Alkaloids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray Source Classification	NF-κB RIP kinase Mixed Lineage Kinase
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as *RIPK3/MLKL* signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	Flavonoids Oleaceae Classification of Application Fields Flavones Ligustrum lucidum Ait. Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the *RIPK1/RIPK3/MLKL* pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the *RIPK1/RIPK3/MLKL* pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-N1535

Ponicidin 4 Publications Verification Rubescensine B	Structural Classification other families Classification of Application Fields Terpenoids Labiatae Diterpenoids Plants Inflammation/Immunology Disease Research Fields Butea monosperma Kuntze Source Classification	Apoptosis Reactive Oxygen Species (ROS)
Ponicidin is an apoptosis inducer, cell growth inhibitor and neuroprotective agent, with a K_a of 135 nM for mouse *RIPK1. Ponicidin regulates the JAK2/STAT3* pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, inhibits inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing Aβ plaque deposition. Ponicidin is applicable to research related to hepatocellular carcinoma, Alzheimer's disease and gastric cancer .

HY-N0546R

Ligustroflavone (Standard) Nuezhenoside (Standard)	Structural Classification Flavonoids Oleaceae Flavones Ligustrum lucidum Ait. Phenols Polyphenols Plants Source Classification	Reference Standards CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the *RIPK1/RIPK3/MLKL* pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the *RIPK1/RIPK3/MLKL* pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

Recombinant Proteins Recommended:

RIPK

Species:	Human (4) Mouse (2) Rat (1) Cynomolgus (2) Dog (1)
Tag:	His (5) GST (6)
Source:	P. pastoris (3) Sf9 insect cells (6) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702936

	RIPK1 Protein, Cynomolgus (Active, sf9, GST) Receptor interacting serine/threonine kinase 1; RIPK1	Cynomolgus	Sf9 insect cells
	RIPK1 Protein, Cynomolgus (Active, sf9, GST) is the recombinant cynomolgus-derived RIPK1, expressed by Sf9 insect cells , with N-GST labeled tag. ,

HY-P703063

	RIPK1 Protein, Canine (Active, sf9, GST) Receptor interacting serine/threonine kinase 1; RIPK1	Dog	Sf9 insect cells
	RIPK1 Protein, Canine (Active, sf9, GST) is the recombinant dog-derived RIPK1, expressed by Sf9 insect cells , with GST labeled tag.

HY-P702935

	RIPK1 Protein, Rat (Active, sf9, GST) Receptor interacting serine/threonine kinase 1 Imported; RIPK1	Rat	Sf9 insect cells
	RIPK1 Protein, Rat (Active, sf9, GST) is the recombinant rat-derived RIPK1, expressed by Sf9 insect cells , with N-GST labeled tag. ,

HY-P703061

	RIPK1 Protein, Cynomolgus (Active, 373a.a, sf9, GST) Receptor interacting serine/threonine kinase 1; RIPK1	Cynomolgus	Sf9 insect cells
	RIPK1 Protein, Cynomolgus (Active, 373a.a, sf9, GST) is the recombinant cynomolgus-derived RIPK1, expressed by Sf9 insect cells , with GST labeled tag.

HY-P71855

	RIPK3 Protein, Human (P.pastoris, His) Receptor interacting protein 3; Receptor interacting serine threonine kinase 3; RIP like protein kinase 3; RIP-3; RIP-like protein kinase 3; RIPK 3	Human	P. pastoris
	RIPK3 is a kinase that controls necroptosis and apoptosis. In necroptosis, activated by TNF-α and ZBP1, RIPK3 phosphorylates MLKL, leading to membrane damage. RIPK3 Protein, Human (P.pastoris, His) is the recombinant human-derived RIPK3 protein, expressed by P. pastoris , with N-6*His labeled tag.

HY-P701768

	RIPK1 Protein, Human (sf9, His, GST) RIPK1; Receptor-interacting serine/threonine-protein kinase 1; Cell death protein RIP; Receptor-interacting protein 1; RIP-1	Human	Sf9 insect cells
	RIPK1 protein is a serine-threonine kinase that centrally regulates TNF-mediated apoptosis, necroptosis, and inflammatory pathways. Functionally, it plays a kinase-dependent role in the regulation of cell death and a kinase-independent scaffolding function in the control of inflammatory signaling and cell survival. RIPK1 Protein, Human (sf9, His, GST) is the recombinant human-derived RIPK1 protein, expressed by sf9 insect cells , with N-8*His, N-GST labeled tag.

HY-P704200

	RIPK1 Protein, Mouse (C-His) RIPK1; Rinp; Rip; Receptor-interacting serine/threonine-protein kinase 1; EC 2.7.11.1; Cell death protein RIP; Receptor-interacting protein 1; RIP-1	Mouse	E. coli
	RIPK1 Protein, Mouse (C-His) is the recombinant mouse-derived RIPK1 protein, expressed by E. coli, with C-6*His tag.

HY-P71853

	RIPK3 Protein, Mouse (P.pastoris, His) RIPK3; Rip3; Receptor-interacting serine/threonine-protein kinase 3; EC 2.7.11.1; RIP-like protein kinase 3; Receptor-interacting protein 3; RIP-3; mRIP3	Mouse	P. pastoris
	RIPK3 Protein, participates in programmed necrosis (necroptosis) and apoptosis, contributing to diverse cellular processes. RIPK3 Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived RIPK3 protein, expressed by P. pastoris , with N-6*His labeled tag.

HY-P705636

	RIPK3 Protein, Human (Active, sf9, GST) Receptor-interacting serine/threonine-protein kinase 3; RIP-like protein kinase 3; Receptor-interacting protein 3; RIP-3	Human	Sf9 insect cells

HY-P700624

	RIPK2 Protein, Human (P. pastoris, His) receptor-interacting serine-threonine kinase 2; receptor-interacting serine/threonine-protein kinase 2; CARD3; CARDIAK; RICK; RIP2; RIP-2; CARD-carrying kinase; growth-inhibiting gene 30; tyrosine-protein kinase RIPK2; receptor interacting protein 2; receptor-interacting protein 2; RIP-like-interacting CLARP kinase; CARD-containing IL-1 beta ICE-kinase; CARD-containing interleukin-1 beta-converting enzyme-associated kinase; CARD-containing interleukin-1 beta-converting enzyme (ICE)-associated kinase; receptor-interacting protein (RIP)-like interacting caspase-like apoptosis regulatory protein (CLARP) kinase; CCK; GIG30;	Human	P. pastoris
	RIPK2 is a multifunctional serine/threonine/tyrosine protein kinase that coordinates innate and adaptive immune responses. It is activated by bacterial peptidoglycan to form filaments in the NOD1 and NOD2 pathways, undergoing autophosphorylation and polyubiquitination. RIPK2 Protein, Human (P. pastoris, His) is the recombinant human-derived RIPK2 protein, expressed by P. pastoris , with C-6His, C-6His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-178762S

RIPK1-IN-35

RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC₅₀ of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis .

Host:	Mouse (5) Rabbit (8)
Reactivity:	Human (10) Rat (1) Mouse (7)
Application:	IHC-P (4) ICC/IF (7) IP (1) WB (9) FC (6) ELISA (5)
Isotype:	IgG (8) IgG1 (4) IgG2b (1)
Conjugation:	Non-conjugated (13)
Clonality:	Monoclonal (9) Recombinant (4)
Modification:	Phosphorylated (1) Unmodified (8)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84632

	LRRK2 Antibody (YA4329) PARK8; RIPK7; ROCO2; AURA17; DARDARIN	ICC/IF, FC, ELISA	Human
	LRRK2 Antibody (YA4329) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.

HY-P84633

	LRRK2 Antibody (YA4330) PARK8; RIPK7; ROCO2; AURA17; DARDARIN	IHC-P, FC, ELISA	Human
	LRRK2 Antibody (YA4330) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.

HY-P80313

	RIP Antibody (YA091) RIP1, RIPK1, Receptor-Interacting Protein Kinase 1	WB, FC	Human
	RIP Antibody (YA091) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP.

HY-P86351

	RIP3 Antibody (YA6043) Receptor-interacting serine/threonine-protein kinase 3, RIPK3,RIP3	WB, ICC/IF, IP, ELISA	Mouse
	RIP3 Antibody (YA6043) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP3.

HY-P84632A

	LRRK2 Antibody (YA4329)(PBS only) PARK8; RIPK7; ROCO2; AURA17; DARDARIN	ICC/IF, FC, ELISA	Human
	LRRK2 Antibody (YA4329) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.

HY-P84633A

	LRRK2 Antibody (YA4330)(PBS only) PARK8; RIPK7; ROCO2; AURA17; DARDARIN	IHC-P, FC, ELISA	Human
	LRRK2 Antibody (YA4330) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.

HY-P810290

	Phospho-RIP3 (S232) Antibody (YA9633) Receptor-interacting serine/threonine-protein kinase 3, RIPK3,RIP3	WB	Mouse
	Phospho-RIP3 (S232) Antibody (YA9633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP3.

HY-P810537

	Phospho-RIP3 (Ser232) Antibody (YA9807) Receptor interacting protein 3; Receptor interacting serine threonine kinase 3; Receptor interacting serine/threonine protein kinase 3; Receptor-interacting protein 3; Receptor-interacting serine/threonine-protein kinase 3; RIP 3; RIP like protein kinase 3; RIP-3; RIP-like protein kinase 3; RIPK 3	WB, ICC/IF	Mouse, Rat
	Phospho-RIP3 (Ser232) Antibody (YA9807) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-RIP3 (Ser232).

HY-P83076

	LRRK2 Antibody (YA2821) AURA17; Dardarin antibody; ; Leucine rich repeat kinase 2; LRRK 2 antibody; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2	WB, IHC-P, ICC/IF	Human, Mouse
	LRRK2 Antibody (YA2821) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LRRK2.

HY-P810542

	Phospho-LRRK2 (Ser935) Antibody (YA9811) AURA17; Dardarin; ; Leucine rich repeat kinase 2; LRRK 2; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2	WB, ICC/IF, FC	Human, Mouse
	Phospho-LRRK2 (Ser935) Antibody (YA9811) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-LRRK2 (Ser935).

HY-P83076A

	Phospho-LRRK2(Ser935) Antibody (YA3424) AURA17; Dardarin antibody; ; Leucine rich repeat kinase 2; LRRK 2 antibody; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2	WB, ICC/IF	Human, Mouse
	Phospho-LRRK2(Ser935) Antibody (YA3424) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-LRRK2(Ser935).

HY-P87052

	RIPK2 Antibody (YA6745) CARD 3 antibody; CARD carrying kinase antibody; CARD containing ICE associated kinase antibody; CARD containing IL 1 beta ICE kinase antibody; CARD containing IL1 beta ICE kinase antibody; CARD containing interleukin 1 beta converting enzyme (ICE) associated kinase antibody; CARD containing interleukin 1 beta converting enzyme associated kinase antibody; CARD-containing IL-1 beta ICE-kinase antibody; CARD-containing interleukin-1 beta-converting enzyme-associated kinase antibody; CARD3 antibody; CARD 3 antibody; CARD carrying kinase antibody; CARD containing ICE associated kinase antibody; CARD containing IL 1 beta ICE kinase antibody; CARD containing IL1 beta ICE kinase antibody; CARD containing interleukin 1 beta converting enzyme (ICE) associated kinase antibody; CARD containing interleukin 1 beta converting enzyme associated kinase antibody; CARD-containing IL-1 beta ICE-kinase antibody; CARD-containing interleukin-1 beta-converting enzyme-associated kinase antibody; CARD3 antibody; CARDIAK antibody; CCK antibody; CLARP kinase antibody; GIG 30 antibody; GIG30 antibody; Growth inhibiting gene 30 antibody; Receptor interacting protein (RIP) like interacting caspase like apoptosis regulatory protein (CLARP) kinase antibody; Receptor interacting protein 2 antibody; Receptor interacting serine threonine kinase 2 antibody; Receptor interacting serine/threonine protein kinase 2 antibody; Receptor-interacting protein 2 antibody; Receptor-interacting serine/threonine-protein kinase 2 antibody; RICK antibody; R; IP : 2 antibody; R; IP : like interacting CLARP kinase antibody; RIP-2 antibody; RIP-like-interacting CLARP kinase antibody; RIPK 2 antibody; RIPK2 antibody; RIPK2_HUMAN antibody; TNFRSF antibody; Tyrosine-protein kinase RIPK2 antibody; UNQ277/PRO314/PRO34092 antibody;	WB	Human
	RIPK2 Antibody (YA6745) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIPK2.

HY-P87337

	LRRK1 Antibody (YA7020) KIAA1790 antibody; Leucine rich repeat serine/threonine protein kinase 1 antibody; Leucine-rich repeat serine/threonine-protein kinase 1 antibody; LRRK 1 antibody; Lrrk1 antibody; LRRK1_HUMAN antibody; RIPK6 antibody; Roco1 antibody	WB, IHC-P	Human, Mouse
	LRRK1 Antibody (YA7020) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to LRRK1.